<DOC>
	<DOCNO>NCT00641407</DOCNO>
	<brief_summary>The maintenance nearly normal glycemic level reduces risk diabetic complication , difficult achieve , despite administration escalate dos oral antidiabetic drug , metformin , sulfonylurea , thiazolidinediones . Most patient eventually require insulin usually add glycemic control regimen oral antidiabetic agent become suboptimal . The aims present study : 1 ) To compare clinical efficacy insulin glargine neutral protamine lispro ( NPL ) insulin add ongoing oral therapy poorly control type 2 diabetic patient ; 2 ) find possibility phenotype patient may benefit single treatment . This open-label , randomize , parallel , 36-week comparative study perform January 2007 March 2008 single centre .</brief_summary>
	<brief_title>Bedtime Insulins Oral Antihyperglycemic Drugs Type 2 Diabetes</brief_title>
	<detailed_description>Patients randomize either NPL ( Lilly ) glargine ( Lantus , Aventis ) administer subcutaneously bedtime . Both insulin formulation consist cartridge contain 3 ML either insulin preparation . Oral antihyperglycemic agent continue prestudy dosage . No dietary advice give beyond reinforcement standard guideline . The initial bedtime insulin dose 10 IU patient goal achieve target FPG &lt; 100 mg/dL group . The insulin dose titrate weekly accord daily self-monitored fasting blood glucose measurement provide value correspond closely laboratory measurement plasma glucose . The patient taught increase insulin dose 2 IU FPG great 100 mg/dL , 4 IU FPG great 180 mg/dL three consecutive morning . Before start insulin therapy , week 12 , 24 36 , blood withdrawn measurement full blood count , electrolyte , creatinine , liver enzymes lipid . Insulin dose , self-monitored plasma glucose ( SMPG ) , event associate sign symptom hypoglycaemia record diary .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Men woman age 3070 year , duration know diabetes &gt; 2 year And treat stable dos two oral antihyperglycemic agent ( metformin sulfonylurea ) least 90 day select study Body mass index less 40 kg/m2 HbA1c level 7.5 10 % And fasting plasma glucose 120 mg/dL great . Exclusion criterion include pregnancy breastfeed Previous use insulin antihyperglycemic drug Investigational drug within previous 3 month Use agent affect glycemic control ( systemic glucocorticoid , weightloss drug ) Presence clinically relevant somatic mental disease To minimize likelihood include subject lateonset type 1 diabetes Candidate positive test antiGAD antibody fast plasma Cpeptide le 0.25 pmol/ml exclude Also exclude patient abnormal safety laboratory test Including liver enzyme ( ALT , AST , AFOS ) high three time upper limit normal serum creatinine &gt; 1.4 mg/dL ) History drug abuse Poor compliance 8point daily glucose profile measurement</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Bedtime insulin</keyword>
	<keyword>Poorly control type 2 diabetes</keyword>
	<keyword>Glycemic control</keyword>
	<keyword>HbA1c</keyword>
</DOC>